The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Lavra, Luca ^a   Rinaldo, Cinzia ^b   Ulivieri, Alessandra ^a   Luciani, Emidio ^c   Fidanza, Paolo ^a   Giacomelli, Laura ^d   Bellotti, Carlo ^e   Ricci, Alberto ^d   Trovato, Maria ^f   Soddu, Silvia ^b   Bartolazzi, Armando ^c,g   Sciacchitano, Salvatore ^a,d  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c Department of Pathology   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF MESSINA   (Italy)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GALECTIN 3; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; MESSENGER RNA; PROTEIN P53; CARRIER PROTEIN; HIPK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ARTICLE; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; DOWN REGULATION; ENZYME ACTIVITY; ENZYME DEFICIENCY; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PLASMID; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA ANALYSIS; RNA INTERFERENCE; THYROID ADENOMA; THYROID HYPERPLASIA; THYROID PAPILLARY CARCINOMA; TUMOR SUPPRESSOR GENE; UPREGULATION; ADULT; AGED; CELL DIFFERENTIATION; CHROMOSOME 7; FEMALE; GENE EXPRESSION; GENETICS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; ONCOGENE; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; CARRIER PROTEINS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 7; FEMALE; GALECTIN 3; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; ONCOGENES; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYROID NEOPLASMS;

EID: 79959209171     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020665     Document Type: Article

References (43)

1. Rinaldo C, Siepi F, Prodosmo A, Soddu S, (2008) HIPKs: Jack of all trades in basic nuclear activities. Biochimica et Biophysica Acta 1783: 2124-2129.
2. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, et al. (2002) Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 4 (1): 11-19.
3. Hofmann TG, Möller A, Sirma H, Zentgraf H, Taya Y, et al. (2002) Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol 4 (1): 1-10.
4. Calzado MA, Renner F, Roscic A, Schmitz ML, (2007) HIPK2: a versatile switchboard regulating the transcription machinery and cell death. Cell Cycle 6: 139-143.
5. Rinaldo C, Prodosmo A, Siepi F, Soddu S, (2007) HIPK2: a multitalented partner for transcription factors in DNA damage response and development. Biochem Cell Biol 85 (4): 411-418.
6. Li XL, Arai Y, Harada H, Shima Y, Yoshida H, et al. (2007) Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1- and p53-mediated transcription. Oncogene 26: 7231-7239.
7. Pierantoni GM, Rinaldo C, Mottolese M, Di Benedetto A, Esposito F, et al. (2007) High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. J Clin Invest 117: 693-702.
8. Pierantoni GM, Fedele M, Pentimalli F, Benvenuto G, Pero R, et al. (2001) High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth. Oncogene 20: 6132-6141.
9. Pierantoni GM, Bulfone A, Pentimalli F, Fedele M, Iuliano R, et al. (2002) The homeodomain-interacting protein kinase 2 gene is expressed late in embryogenesis and preferentially in retina, muscle, and neural tissues. Biochem Biophys Res Commun 290: 942-947.
10. Cecchinelli B, Lavra L, Rinaldo C, Iacovelli S, Gurtner A, et al. (2006) Repression of the antiapoptotic molecule galectin-3 by homeodomain-interacting protein kinase 2-activated p53 is required for p53-induced apoptosis. Mol Cell Biol 26: 4746-4757.
11. Fukumori T, Kanayama HO, Raz A, (2007) The role of galectin-3 in cancer drug resistance. Drug Resist Updat 10: 101-108.
12. Nakahara S, Oka N, Raz A, (2005) On the role of galectin-3 in cancer apoptosis. Apoptosis 10: 267-275.
13. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A, (1997) Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 57: 5272-5276.
14. Yu F, Finley RL Jr, Raz A, Kim HR, (2002) Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem 277: 15819-15827.
15. Danguy A, Camby I, Kiss R, (2002) Galectins and cancer. Biochim Biophys Acta 1572: 285-293.
16. Yoshii T, Inohara H, Takenaka Y, Honjo Y, Akahani S, et al. (2001) Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol 18: 787-792.
17. Lin CI, Whang EE, Donner DB, Jiang X, Price BD, et al. (2009) Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer. Mol Cancer Res 7: 1655-1662.
18. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, et al. (2001) Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357: 1644-1650.
19. Lavra L, Ulivieri A, Rinaldo C, Dominici R, Volante M, et al. (2009) Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. J Pathol 218: 66-75.
20. Bartolazzi A, Orlandi F, Saggiorato E, Volante M, Arecco F, et al. (2008) Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol 9: 543-549.
21. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, et al. (1993) High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91: 179-184.
22. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, et al. (1993) Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91: 1753-1760.
23. Lazzereschi D, Sambuco L, Carnovale Scalzo C, Ranieri A, Mincione G, et al. (1998) Cyclin D1 and Cyclin E expression in malignant thyroid cells and in human thyroid carcinomas. Int J Cancer 76: 806-811.
24. Bártek J, Bártková J, Lukás J, Stasková Z, Vojtsek B, et al. (1993) Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J Pathol 169: 27-34.
25. Trovato M, Ulivieri A, Dominici R, Ruggeri RM, Vitarelli E, et al. (2004) Clinico-pathological significance of cell-type-specific loss of heterozygosity on chromosome 7q21: analysis of 318 microdissected thyroid lesions. Endocr Relat Cancer 11: 365-376.
26. Kitamura Y, Shimizu K, Ito K, Tanaka S, Emi M, (2001) Allelotyping of follicular thyroid carcinoma: frequent allelic losses in chromosome arms 7q, 11p, and 22q. J Clin Endocrinol Metab 86: 4268-4272.
27. Zhang JS, Nelson M, McIver B, Hay ID, Goellner JR, et al. (1998) Differential loss of heterozygosity at 7q31.2 in follicular and papillary thyroid tumors. Oncogene 17: 789-793.
28. Robbins J, Schneider AB, (2000) Thyroid cancer following exposure to radioactive iodine. Rev Endocr Metab Disord 1: 197-203.
29. Schneider AB, Sarne DH, (2005) Long-term risks for thyroid cancer and other neoplasms after exposure to radiation. Nat Clin Pract Endocrinol Metab 1: 82-91.
30. Nikiforov YE, (2010) Is ionizing radiation responsible for the increasing incidence of thyroid cancer? Cancer 116: 1626-1628.
31. Iacovelli S, Ciuffini L, Lazzari C, Bracaglia G, Rinaldo C, et al. (2009) HIPK2 is involved in cell proliferation and its suppression promotes growth arrest independently of DNA damage. Cell Prolif 42: 373-384.
32. Shimamura T, Sakamoto M, Ino Y, Shimada K, Kosuge T, (2002) Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clin Cancer Res 8: 2570-2575.
33. Piantelli M, Iacobelli S, Almadori G, Iezzi M, Tinari N, et al. (2002) Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. J Clin Oncol 20: 3850-3856.
34. Okada K, Shimura T, Suehiro T, Mochiki E, Kuwano H, (2006) Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer. Anticancer Res 26: 1369-1376.
35. Kawachi K, Matsushita Y, Yonezawa S, Nakano S, Shirao K, et al. (2000) Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol 31: 428-433.
36. Huang H, Reed CP, Mordi A, Lomberk G, Wang L, et al. (1999) Frequent deletions within FRA7G at 7q312 in invasive epithelial ovarian cancer. Genes Chromosomes Cancer 24: 48-55.
37. Zenklusen JC, Hodges LC, LaCava M, Green ED, Conti CJ, (2000) Definitive functional evidence for a tumor suppressor gene on human chromosome 7q31.1 neighboring the Fra7G site. Oncogene 19: 1729-1733.
38. Han SY, Druck T, Huebner K, (2003) Candidate tumor suppressor genes at FRA7G are coamplified with MET and do not suppress malignancy in a gastric cancer. Genomics 81: 105-107.
39. Li Volsi VA, Albores-SaAvedra J, Asa SL, Baloch ZW, Sobrinho-Simoes M, et al. (2004) Tumours of thyroid and parathyroid. In WHO Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. Geneva/IARC, Lyon World Health Organization pp. 49-100.
40. Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, et al. (2007) Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 31: 1256-1264.
41. Ulivieri A, Lavra L, Dominici R, Giacomelli L, Brunetti E, et al. (2008) Frizzled-1 is down-regulated in follicular thyroid tumours and modulates growth and invasiveness. J Pathol 215: 87-96.
42. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
43. Kong A, Gudbjartsson DF, Sainz J, Jonsdottir GM, Gudjonsson SA, et al. (2002) A high-resolution recombination map of the human genome. Nat Genet 31: 241-247.